Abstract In order to assess the incidence and possible predisposing and contributing factors in the development of acute pancreatitis after liver transplantation, we reviewed the medical records of all 1832 adult patients who underwent 2161 orthotopic liver transplantation (OLTx) procedures in our center between January 1987 and September 1992. Of these patients, 55 (3 % incidence) developed clinical pancreatitis and 247 (13.4 % incidence) developed hyperamylasemia (biochemical pancreatitis). Overall mortality in cases of clinical pancreatitis was 63.6 %. The mortality in cases of hyperamylasemia was similar to that found in the general liver transplant population (i. e., 23 %). A strong correlation was found between pancreatitis after liver transplantation and end-stage liver disease due to hepatitis B (30 % of the cases, P = 0.00001). Extensive surgical dissection around the pancreas (P < 0.05), the type of biliary reconstruction following liver transplantation (P < 0.05), and the number of liver grafts received by the same patient (P --0.00001) appeared to be possible contributing factors as did the duration of venovenous bypass and the quantity of IV calcium chloride administered intraoperatively.
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Introduction
Pancreatitis constitutes one of the most severe complications following liver transplantation. In the general population, it has been postulated that ischemia [38] , drugs (i. e., steroids [3, 5, 23, 31] , furosemide [7, 15, 39] , unidentified viral infections [2, 4] , postoperative hyperparathyroidism, vasculitis, calcium chloride administration [21, 29, 36] , and intraoperative trauma may all be contributing factors. Alexander et al.
[1] reported a high incidence of post-OLTx (orthotopic liver transplantation) pancreatitis in patients suffering from hepatitis B. In fact, a report from the same institution revealed the magnitude of the problem and raised questions for further study [26] . To gain further insight into this problem, a retrospective analysis of the incidence of post-OLTx pancreatitis was undertaken. A main objective was to identify the variables most strongly associated with pancreatitis after OLTx.
Materials and methods
From 1 January 1987 to 30 September 1992, 1832 patients underwent 2161 OLTx procedures at the Presbyterian University Hospital of Pittsburgh. Of these patients, 302 developed postoperative hyperamylasemia, and all of their records were reviewed. This report deals with post-OLTx pancreatitis in the immediate postoperative period (up to 30 days after OLTx). In fact, most of these patients developed this complication during the 1st postoperative week, and mostly in the intensive care unit (ICU). Apart from hepatitis B-positive serology, which has been shown to predispose patients to the development of pancreatitis, no other preoperative contributing condition was identified. For the purpose of this study, patients with hyperamylasemia who had serum creatinine above 2 mg were excluded, since measurements of creatinine and amylase clearance were lacking.
Amylase was determined every other day in the immediate posttransplant period or more frequently when indicated. Serum amylase measurements were performed using the Kodak Enzymatic Amylase Kit (Eastman Kodak, Rochester, N.Y.).
Clinical pancreatitis was defined as an elevation of the serum amylase level in excess of twice the value of the normal upper limit, plus any additional diagnostic CT scan findings (such as pancreatic enlargement or pseudocyst/abscess formation), intraoperative findings, or autopsy confirmation. Clinical findings were not considered because they were ill-defined. Patients diagnosed as having ctinical pancreatitis were immediately brought to the ICU postoperatively; most of them were on mechanical ventilation. Patients whose amylase levels were elevated to more than twice the normal upper limit, at least in one measurement, were defined as having hyperamylasemia (biochemical pancreatitis). This term was first used by Alexander et al.
[1], and we used it for all patients with hyperamylasemia who lacked the clinical or CT findings consistent with pancreatitis. Of course, the use of creatinine clearance values in the assessment of renal function is more reliable than that of serum creatinine levels. However, we chose to use the 2-mg serum creatinine threshold, based on the above-mentioned reference by Alexander et al. Moreover, in this retrospective study, it was not feasible to obtain creatinine clearance values for all of our patients.
All the patients who developed clinical pancreatitis wee put on either double or single venovenous bypass. Double bypass is considered when the femoral and portal veins are brought together to a centripetal pump (Bio-Medicus, Minnetonka, Minn.) and the return flow is connected to the axillary vein. Single bypass was the choice in cases of previous portocaval shunts or portal vein thrombosis or when the portal vein was unsuitable for double bypass. The liver grafts were harvested according to the technique described by Starzl et al. [33] .
From 1987 until 1989 cyclosporin (CyA) plus steroids was the standard immunosuppressive treatment for liver recipients. For rejection episodes a bolus dose of steroids was administered intravenously, followed by a steroid recycling protocol. If there was no response, a course of OKT3 was given intravenously. Starting in 1989, FK 506 replaced CyA in the protocols used, and the steroid doses were significantly lowered because of the greater FK 506 potency. The antirejection treatment remained unchanged. Until bowel function had resumed, lipids in the form of total parenteral nutrition (TPN) were administered as a postoperative rule. No difference was found regarding the incidence or severity of pancreatitis between groups of patients treated with CyA and those treated with FK 506. In all patients undergoing surgical treatment, intraabdominal sepsis was documented preoperatively.
Neither Ranson score nor other criteria were used to assess the severity of pancreatitis, since most of these are greatly deranged following liver transplantation. The therapeutic choice was based mostly on the abdominal CT findings. Furthermore, in most of the cases dynamic CT pancreatography was carried out in order to assess the extent of the necrosis.
Treatment of clinical pancreatitis was either medical or surgical. Surgical treatment included simple drainage, debridement, or pancreatectomy.
Statistical analysis was performed using Student's t-test for unpaired samples. The chi-square method was used to evaluate the association and the differences in proportions. A P value below 0.05 was considered to be significant.
Results
Of the 1832 patients who were studied, 302 (16.4 %) developed hyperamylasemia during the postoperative course of O L T x without renal insufficiency (serum creatinine < 2 mg %). Of these, 55 (3 %) developed clinical pancreatitis; in the other 247 patients, amylase levels eventually returned to normal.
Of the 55 patients who developed clinical pancreatitis, 17 (30.9 %) had been transplanted because of hepatitis B cirrhosis, as compared to 114 (6.2 %) of the total number of liver transplant recipients who had been transplanted for the same reason. Fifteen patients who later developed clinical pancreatitis (27.3 %) had been transplanted for hepatitis non-A non-B cirrhosis, as against 340 (18.6 %) of the total n u m b e r of liver transplant recipients. Eight patients (14.5 %) versus 172 patients (9.4 %) had been transplanted for primary biliary cirrhosis, while 7 (12.7 %) versus 310 (16.9 %) had been transplanted for alcoholic cirrhosis. Three patients (5.4 %) versus six (0.3 %) had been transplanted for fulminant hepatic failure related to drug overdose. Two patients (3.6 %) versus 129 (7.0 %) had been transplanted for primary sclerosing cholangitis. Two patients (3.6 %) versus 82 (4.5 %) had been transplanted for hepatocellular carcinoma. Finally, 1 patient who developed clinical pancreatitis (1.8 %) versus 59 (3.2%) of the total number of liver transplant recipients had been transplanted for autoimmune hepatitis (Fig. 1) . This distribution of diseases necessitating O L T x among patients who later developed clinical pancreatitis was statistically highly significant (P = 0.00001) compared with the distribution among all liver transplant recipients.
Of the 55 patients with clinical pancreatitis, 40 (72.7 %) had received FK 506 plus steroids as immunosuppressive treatment, and 15 (27.2 %) had received C y A plus steroids. All of the patients had also been treated with furosemide.
The annual distribution of these 55 cases of post-O L T x pancreatitis was: 8 patients (14.5 %) for the year 1987, 5 patients ( 9 % ) for the year 1988, 12 patients (21.8 %) for the year 1989, 12 ptients (21.8 %) for the year 1990, 13 patients (23.6 %) for the year 1991, and 5 patients (9 %) for the first 9 months of 1992. This distribution is not statistically significant compared to the annual distribution of O L T x procedures for the entire liver transplant population during the same time period (Table 1 ). The mean age of these 55 patients was 47.1 years (SD + 14.2), with a range between 20 and 69 years. The mean age of all liver transplant patients was 47.0 years (SD + 12.7). The difference between the two groups is not statistically significant. The distribution according to age groups is shown in Fig. 2 .
Twenty-nine (52.7 %) of the 55 patients who developed post-OLTx pancreatitis had received primary liver grafts. Twenty patients (36.3 %) developed pancrea-
